TY - JOUR
T1 - Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum
T2 - Report of a case
AU - Lo, Shelly S.
AU - Papachristou, Georgios I.
AU - Finkelstein, Sydney D.
AU - Conroy, William P.
AU - Schraut, Wolfgang H.
AU - Ramanathan, Ramesh K.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/6
Y1 - 2005/6
N2 - Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract. Gastrointestinal stromal tumors involving the rectum are uncommon. We describe a case of a 43-year-old female with a gastrointestinal stromal tumor of the rectum who declined abdominoperineal resection. Neoadjuvant treatment with imatinib decreased her tumor size, permitting sphincter-sparing transanal excision. She had no evidence of disease for 24 months postoperatively until she recurred with lung metastases. Microdissection genotyping of the recurrent lesion revealed a deletion in exon 11. Further mutational analysis showed that her metastatic lesion was concordant with her primary rectal lesion, suggesting that systemic micrometastasis was previously present at initial diagnosis. Deletion in exon 11 predicts for response with imatinib treatment and is associated with a longer event-free and overall survival. Current studies are underway that may help us optimize the treatment for patients with gastrointestinl stromal tumors.
AB - Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract. Gastrointestinal stromal tumors involving the rectum are uncommon. We describe a case of a 43-year-old female with a gastrointestinal stromal tumor of the rectum who declined abdominoperineal resection. Neoadjuvant treatment with imatinib decreased her tumor size, permitting sphincter-sparing transanal excision. She had no evidence of disease for 24 months postoperatively until she recurred with lung metastases. Microdissection genotyping of the recurrent lesion revealed a deletion in exon 11. Further mutational analysis showed that her metastatic lesion was concordant with her primary rectal lesion, suggesting that systemic micrometastasis was previously present at initial diagnosis. Deletion in exon 11 predicts for response with imatinib treatment and is associated with a longer event-free and overall survival. Current studies are underway that may help us optimize the treatment for patients with gastrointestinl stromal tumors.
KW - Gastrointestinal stromal tumor
KW - Imatinib
KW - Microdissection genotyping
KW - Rectal tumor
UR - http://www.scopus.com/inward/record.url?scp=21244447695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=21244447695&partnerID=8YFLogxK
U2 - 10.1007/s10350-004-0922-3
DO - 10.1007/s10350-004-0922-3
M3 - Article
C2 - 15793646
AN - SCOPUS:21244447695
SN - 0012-3706
VL - 48
SP - 1316
EP - 1319
JO - Diseases of the colon and rectum
JF - Diseases of the colon and rectum
IS - 6
ER -